Main results of cost-effectiveness analysis of Model A
| First-line treatment analysis . | VenO . | ClbO . | Incremental . | ICER . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cost, € . | QALY . | Life y . | Cost, € . | QALY . | Life y . | Cost, € . | QALY . | Life y . | (€/QALY) . | |
| Base case | 194 612 | 5.20 | 7.54 | 182 567 | 3.97 | 6.12 | 12 045 | 1.23 | 1.42 | 9807 |
| Same OS curve | 194 612 | 5.20 | 7.54 | 182 567 | 4.68 | 7.54 | 12 045 | 0.52 | 0 | 23 163 |
| Ibrutinib until progression | 206 191 | 5.19 | 7.54 | 200 221 | 3.96 | 6.12 | 5970 | 1.23 | 1.42 | 4841 |
| Only first line | 109 821 | 5.75 | 8.32 | 53 525 | 4.48 | 6.76 | 56 296 | 1.27 | 1.56 | 44 265 |
| Only ibrutinib in second line | 213 373 | 4.98 | 7.18 | 211 161 | 3.64 | 5.58 | 1648 | 1.34 | 1.60 | 2212 |
| Only VenR in second line | 175 850 | 5.42 | 7.89 | 153 972 | 4.30 | 6.66 | 21 878 | 1.11 | 1.23 | 19 644 |
| First-line treatment analysis . | VenO . | ClbO . | Incremental . | ICER . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Cost, € . | QALY . | Life y . | Cost, € . | QALY . | Life y . | Cost, € . | QALY . | Life y . | (€/QALY) . | |
| Base case | 194 612 | 5.20 | 7.54 | 182 567 | 3.97 | 6.12 | 12 045 | 1.23 | 1.42 | 9807 |
| Same OS curve | 194 612 | 5.20 | 7.54 | 182 567 | 4.68 | 7.54 | 12 045 | 0.52 | 0 | 23 163 |
| Ibrutinib until progression | 206 191 | 5.19 | 7.54 | 200 221 | 3.96 | 6.12 | 5970 | 1.23 | 1.42 | 4841 |
| Only first line | 109 821 | 5.75 | 8.32 | 53 525 | 4.48 | 6.76 | 56 296 | 1.27 | 1.56 | 44 265 |
| Only ibrutinib in second line | 213 373 | 4.98 | 7.18 | 211 161 | 3.64 | 5.58 | 1648 | 1.34 | 1.60 | 2212 |
| Only VenR in second line | 175 850 | 5.42 | 7.89 | 153 972 | 4.30 | 6.66 | 21 878 | 1.11 | 1.23 | 19 644 |